Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial.

Rachel B Jones, Shunsuke Furuta, Jan Willem Cohen Tervaert, Thomas Hauser, Raashid Luqmani, Matthew D Morgan, Chen Au Peh, Caroline O Savage, Mårten Segelmark, Vladimir Tesar, Pieter van Paassen, Michael Walsh, Kerstin Westman, David Rw Jayne

Research output: Contribution to journalArticlepeer-review

Abstract

The RITUXVAS trial reported similar remission induction rates and safety between rituximab and cyclophosphamide based regimens for antineutrophil cytoplasm antibody (ANCA)-associated vasculitis at 12 months; however, immunosuppression maintenance requirements and longer-term outcomes after rituximab in ANCA-associated renal vasculitis are unknown.
Original languageEnglish
Pages (from-to)1178-1182
JournalAnnals of the Rheumatic Diseases
Volume74
Issue number6
DOIs
Publication statusPublished - 2015

Subject classification (UKÄ)

  • Clinical Medicine

Fingerprint

Dive into the research topics of 'Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial.'. Together they form a unique fingerprint.

Cite this